Maxim Group LLC Expands Equity Research Platform With the Appointment of a Senior Biotechnology Analyst

NEW YORK, April 30, 2018 (GLOBE NEWSWIRE) — Maxim Group LLC, a leading full service investment banking, securities and wealth management firm today announced the expansion of its Equity Research platform with the appointment of Caroline Palomeque as a Senior Vice President and Senior Biotechnology Analyst.

Prior to joining Maxim Group, Ms. Palomeque was a Senior Research Analyst covering the Biotechnology sector at Noble Life Science Partners and WallachBeth Capital. She has equity research experience at Oppenheimer, JMP Securities, Goldman Sachs, and Natexis Bleichroeder. Ms. Palomeque has conducted research at Mount Sinai School of Medicine in molecular epidemiology and neurotoxins. She also coauthored several scientific papers which were peer-reviewed academic journals. “I am pleased to add someone with Caroline’s experience background to our Healthcare Platform. Healthcare is a core vertical at Maxim Group and Biotechnology is an important component,” said Anthony V. Vendetti, Executive Managing Director and Head of Equity Research at Maxim Group.

Ms. Palomeque holds an M.B.A. in Finance from Fordham University Graduate School of Business and a B.S. in Neuroscience from the University of Massachusetts Amherst.

This entry was posted in 2018 News & Press, News and Press. Bookmark the permalink.